阿得贝利单抗治疗恶性肿瘤的研究进展

Research Progress in Treatment of Malignant Tumors with Adebrelimab

阿得贝利单抗是一种针对程序性细胞死亡配体1的人源化单克隆抗体,也是一种新型免疫检查点抑制剂。阿得贝利单抗凭借其独特的作用机制以及良好的临床疗效已用于广泛期小细胞肺癌的一线治疗。关于阿得贝利单抗在其他恶性肿瘤(非小细胞肺癌、食管鳞状细胞癌、三阴性乳腺癌等)治疗中的研究也已取得一定进展,且目前正在探索不同阶段及不同联合模式下小细胞肺癌的治疗。此外,关于阿得贝利单抗在胆管癌、肝癌等实体瘤中的相关研究也正在进行中。因此,未来深入研究阿得贝利单抗在恶性肿瘤中的作用机制,可以为肿瘤的治疗提供新思路。

Adebrelimab is a humanized monoclonal antibody against programmed cell death ligand 1,which is also a novel immune checkpoint inhibitor.Adbelizumab has been used in the first-line treatment of extensive stage small cell lung cancer with its unique mechanism of action and good clinical efficacy.Some progress has been made in the adebrelimab treatment of other malignant tumors(such as non-small cell lung cancer,esophageal squamous cell carcinoma,triple-negative breast cancer,etc.),and the treatment of small cell lung cancer at different stages and in different combination modes is being explored.In addition,research on adebrelimab in solid tumors such as cholangiocarcinoma and liver cancer are also in progress.Therefore,future in-depth studies of the mechanism of adebrelimab in malignant tumors can provide new ideas for the treatment of tumors.